12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cimzia certolizumab pegol regulatory update

FDA's Arthritis Advisory Committee voted 7-6, with 1 abstention, in favor of approving an sBLA from UCB to expand the label of Cimzia certolizumab pegol to include treatment of active axial spondyloarthritis in adults, including patients with ankylosing spondylitis. The panel voted 13-1 that Cimzia has an adequate safety...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >